Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIP-1095 I-123
- Development stage
- Phase 1
- Lead developer
- Lantheus
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MIP-1095 I-123 is an iodine 123-radiolabeled small molecule that exhibits high affinity for prostate-specific membrane antigen (PSMA). It is a glutamate–urea–lysine analogue designed for molecular imaging of PSMA-expressing prostate cancer cells using gamma scintigraphy. PSMA is highly expressed on malignant prostate epithelial cells and the vascular endothelium of various solid tumors. MIP‑1095 I‑123 selectively binds to PSMA, enabling targeted imaging in patients with suspected or known prostate cancer. The drug has been investigated in clinical trials for its safety, pharmacokinetics, tissue distribution, metabolism, and dosimetry as a diagnostic agent in prostate cancer[1][2][3][4][8].
- Other names
- radiolabeled glutamate-urea-lysine analogue
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on MIP-1095 I-123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIP-1095 I-123.